What should patients pay attention to when using levodopa inhalation powder spray (Inbrija)?

Levodopa (Inbrija) is a medicine used to treat Parkinson's disease (a progressive brain disease that causes tremors, muscle stiffness, and slowed movement) in adults. Levodopa inhalation powder spray is used to treat patients' symptoms during the "off-treatment" period (a period when it is more difficult for the patient to move) during conventional treatment (combination therapy with levodopa and dopa decarboxylase inhibitors). Patients should pay special attention to the following matters when using it. First, do not use levodopa inhalation powder if you have used a monoamine oxidase (MAO) inhibitor such as isocarboxazid, linezolid, methylene blue injection, phenelzine, rasagiline, selegiline, or tranylcypromine in the past 14 days as this may cause dangerous drug interactions.

To ensureInbrija is safe for you, tell your doctor your complete medical history before use, especially if you have: asthma, chronic obstructive pulmonary disease (COPD), or other breathing disorder, because inhaled administration may worsen breathing problems; glaucoma, because levodopa may affect eye pressure; involuntary muscle movements, because levodopa may cause A sleep disorder that causes daytime sleepiness, because the drug may affect alertness; dizziness, nausea, or fainting when standing up from a sitting or lying position, which may be related to low blood pressure; a psychiatric disorder or psychosis, because levodopa may worsen psychiatric symptoms; and strong impulsive or compulsive behaviors (such as sexual urges, overeating, gambling, or spending money), because levodopa may trigger or worsen these behaviors.

Also, it is not known whether inhalationInbrija will cause harm to an unborn baby. If you are pregnant or plan to become pregnant, tell your doctor before use so the potential risks can be assessed and an appropriate treatment plan can be developed. By fully communicating and strictly following the doctor's instructions, patients can maximize the safety and effectiveness of levodopa inhalation powder while reducing potential risks and side effects.

Reference link:https://www.ema.europa.eu/en/medicines/human/EPAR/inbrija